| NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer |
Advanced Science |
2026-02 |
OMIX004302
OMIX004425
More
|
Deposit |
| Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2− breast cancer |
Cell Reports Medicine |
2025-01 |
OMIX004302
OMIX004425
More
|
Deposit |
| Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer |
Nature Communications |
2023-08 |
OMIX004302
OMIX004425
More
|
Deposit |
| Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases |
Nature Communications |
2026-05 |
OMIX008056
OMIX014627
OMIX004302
OMIX004425
More
|
Secondary use |
| Immune-stromal heterogeneity in breast cancer across diverse ancestries: impact on prognosis and treatment response |
NPJ Breast Cancer |
2025-12 |
OMIX004425
OMIX004302
More
|
Secondary use |
| Multicenter radio-multiomic analysis for predicting breast cancer outcome and unravelling imaging-biological connection |
NPJ Precision Oncology |
2024-09 |
OMIX004302
OMIX004425
More
|
Deposit |
| Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer |
Proceedings of the National Academy of Sciences |
2026-03 |
OMIX004302
OMIX004425
More
|
Deposit |
| The HLA-I landscape confers prognosis and antitumor immunity in breast cancer |
Briefings in Bioinformatics |
2024-05 |
OMIX004425
OMIX004302
More
|
Deposit |
| Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study |
The Oncologist |
2024-07 |
OMIX004302
OMIX004425
More
|
Secondary use |
| MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancer |
The Journal of Clinical Investigation |
2024-11 |
OMIX004425
OMIX004302
More
|
Deposit |
| A fusion-deletion genomic-event underlies poor prognosis in young patients with luminal breast cancer |
PLOS One |
2026-06 |
OMIX004425
OMIX004302
More
|
Deposit |
| Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer |
Cancer Biology & Medicine |
2024-04 |
OMIX004425
OMIX004302
More
|
Deposit |
| Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors |
Cancer Biology & Medicine |
2026-03 |
OMIX004302
OMIX004424
OMIX004425
More
|
Deposit |
| Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer |
International Journal of Biological Sciences |
2025-06 |
OMIX004302
OMIX004425
More
|
Deposit |